Acambis Gets Positive Recommendations for Smallpox Vaccine
Acambis plc (Cambridge, UK, www.acambis.com) has announced that the Vaccines and Related Biological Products Advisory Committee of the US Food and Drug Administration has voted unanimously that Acambis' ACAM2000 is both safe and efficacious.
Acambis plc (Cambridge, UK, www.acambis.com) has announced that the Vaccines and Related Biological Products Advisory Committee of the US Food and Drug Administration has voted unanimously that Acambis’ ACAM2000 is both safe and efficacious. The Advisory Committee was asked to review whether the clinical data demonstrated that ACAM2000 was safe and effective for use in persons at high risk of exposure to smallpox virus. It voted 11–0 in favor on both the safety and efficacy of ACAM2000. The FDA has identified August 31, 2007, as the target date for its response to Acambis’ ACAM2000 license application under the Prescription Drug User Fee Act.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
